Cargando…
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterized by the accumulation of two proteins in fibrillar form: amyloid-β (Aβ) and tau. Despite decades of intensive research, we cannot yet pinpoint the exact cause of the disease or unequivocally determine the exact mechanis...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492751/ https://www.ncbi.nlm.nih.gov/pubmed/32982716 http://dx.doi.org/10.3389/fnagi.2020.00272 |
_version_ | 1783582429903060992 |
---|---|
author | Bjorkli, Christiana Sandvig, Axel Sandvig, Ioanna |
author_facet | Bjorkli, Christiana Sandvig, Axel Sandvig, Ioanna |
author_sort | Bjorkli, Christiana |
collection | PubMed |
description | Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterized by the accumulation of two proteins in fibrillar form: amyloid-β (Aβ) and tau. Despite decades of intensive research, we cannot yet pinpoint the exact cause of the disease or unequivocally determine the exact mechanism(s) underlying its progression. This confounds early diagnosis and treatment of the disease. Cerebrospinal fluid (CSF) biomarkers, which can reveal ongoing biochemical changes in the brain, can help monitor developing AD pathology prior to clinical diagnosis. Here we review preclinical and clinical investigations of commonly used biomarkers in animals and patients with AD, which can bridge translation from model systems into the clinic. The core AD biomarkers have been found to translate well across species, whereas biomarkers of neuroinflammation translate to a lesser extent. Nevertheless, there is no absolute equivalence between biomarkers in human AD patients and those examined in preclinical models in terms of revealing key pathological hallmarks of the disease. In this review, we provide an overview of current but also novel AD biomarkers and how they relate to key constituents of the pathological cascade, highlighting confounding factors and pitfalls in interpretation, and also provide recommendations for standardized procedures during sample collection to enhance the translational validity of preclinical AD models. |
format | Online Article Text |
id | pubmed-7492751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74927512020-09-25 Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients Bjorkli, Christiana Sandvig, Axel Sandvig, Ioanna Front Aging Neurosci Neuroscience Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterized by the accumulation of two proteins in fibrillar form: amyloid-β (Aβ) and tau. Despite decades of intensive research, we cannot yet pinpoint the exact cause of the disease or unequivocally determine the exact mechanism(s) underlying its progression. This confounds early diagnosis and treatment of the disease. Cerebrospinal fluid (CSF) biomarkers, which can reveal ongoing biochemical changes in the brain, can help monitor developing AD pathology prior to clinical diagnosis. Here we review preclinical and clinical investigations of commonly used biomarkers in animals and patients with AD, which can bridge translation from model systems into the clinic. The core AD biomarkers have been found to translate well across species, whereas biomarkers of neuroinflammation translate to a lesser extent. Nevertheless, there is no absolute equivalence between biomarkers in human AD patients and those examined in preclinical models in terms of revealing key pathological hallmarks of the disease. In this review, we provide an overview of current but also novel AD biomarkers and how they relate to key constituents of the pathological cascade, highlighting confounding factors and pitfalls in interpretation, and also provide recommendations for standardized procedures during sample collection to enhance the translational validity of preclinical AD models. Frontiers Media S.A. 2020-09-02 /pmc/articles/PMC7492751/ /pubmed/32982716 http://dx.doi.org/10.3389/fnagi.2020.00272 Text en Copyright © 2020 Bjorkli, Sandvig and Sandvig. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Bjorkli, Christiana Sandvig, Axel Sandvig, Ioanna Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title | Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title_full | Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title_fullStr | Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title_full_unstemmed | Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title_short | Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients |
title_sort | bridging the gap between fluid biomarkers for alzheimer’s disease, model systems, and patients |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492751/ https://www.ncbi.nlm.nih.gov/pubmed/32982716 http://dx.doi.org/10.3389/fnagi.2020.00272 |
work_keys_str_mv | AT bjorklichristiana bridgingthegapbetweenfluidbiomarkersforalzheimersdiseasemodelsystemsandpatients AT sandvigaxel bridgingthegapbetweenfluidbiomarkersforalzheimersdiseasemodelsystemsandpatients AT sandvigioanna bridgingthegapbetweenfluidbiomarkersforalzheimersdiseasemodelsystemsandpatients |